Scientific Sessions 2024  /  The Future of Lipid Management: Using Lessons From Our Past  /  The Discovery of the LDL-Receptor and It's Potential as a Target
Logo

American Heart Association

  57
  0

Final ID:

The Discovery of the LDL-Receptor and It's Potential as a Target

  • Goldstein, Joseph  ( UTSW MEDICAL CTR , Dallas , Texas , United States )
  • Brown, Michael  ( UT SOUTHWESTERN MED CTR , Dallas , Texas , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Joseph Goldstein: No Answer | Michael Brown: No Answer | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Future of Lipid Management: Using Lessons From Our Past

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
How Low and How Fast Should We Go with LDL-Cholesterol?

Ray Kausik, Lloyd-jones Donald, Tokgozoglu Lale

How Do We Get There with Lipid Lowering Therapy? Implementation Insights

Pagidipati Neha

More abstracts from these authors:
Association of Urine Metabolites with All-Cause and Cause-Specific Mortality: The Atherosclerosis Risk in Communities (ARIC) Study

Zhou Peidi, Yang Yueh-ning, Schlosser Pascal, Hoogeveen Ron, Ballantyne Christie, Yu Bing

Statins and memory

Zhao Bingxin, Ballantyne Christie, Nambi Vijay, Saseen Joseph

You have to be authorized to contact abstract author. Please, Login
Not Available